Notch signaling pathway: dual role in tumour progression and therapeutic opportunities for bladder cancer

During cancer progression Notch signaling pathway and its components could demonstrate oncogenic and tumor-suppressive properties depending on tissue type and cellular microenvironment. However, until recently, very little was known about Notch role in bladder cancer (BC). According to recent studies it was revealed that loss of copy number and decreased expression of NOTCH1 is the hallmark of BC cell lines; and NOTCH1 activation in vitro reduces cell proliferation, suggesting that NOTCH1 acts as a tumor suppressor in BC. Furthermore, BC could be promoted by bladder-specific inactivation of a component of y-secretase complex, which is directly involved in Notch signaling, in vivo. By contrast, further studies have demonstrated that NOTCH2 acts as an oncogene which could promote cell proliferation and metastasis through induction of epithelial-to-mesenchymal transition and maintaining stemness. Studies indicating that NOTCH1 and NOTCH2 have opposite effects on BC progression could give rise to novel therapeutic approaches aimed at impact on Notch activity.

1. Antoni S., Ferlay J., Soerjomataram I. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. PMID: 27370177.

2. Malats N., Real F. X. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 2015;29(2):177—89. DOI: 10.1016/j.hoc.2014.10.001. PMID: 25836927.

3. Rosenberg J.E., Hoffman-Censits J., Pow-les T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387(10031):1909-20. DOI: 10.1016/S0140-6736(16)00561-4. PMID: 26952546.

4. Hussain M.H., Wood D.P., Bajorin D.F. et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 2009;27(34):5680-4. DOI: 10.1200/JCO.2009.23.6901. PMID: 19858384.

5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315-22. DOI: 10.1038/nature12965. PMID: 24476821.

6. Wilson A., Radtke F. Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett 2006;580(12): 2860-8. DOI: 10.1016/j.febs-let.2006.03.024. PMID: 16574107.

7. Weng A.P., Ferrando A.A., Lee W. et al. Activating mutations of NOTCH1 in human T-cell acute lymphoblastic leukemia. Science 2004;306(5694):269—71. DOI: 10.1126/science.1102160. PMID: 15472075.

8. Lin C., Zheng H., Wang C. et al. Mutations increased overexpression of Notch1 in T-cell acute lymphoblastic leukemia. Cancer Cell Int 2012;12:13. DOI: 10.1186/1475-2867-12-13. PMID: 22480166.

9. Clay M.R., Varma S., West R.B. MAST2 and NOT CH1 translocations in breast carcinoma and associated pre-invasive lesions. Hum Pathol 2013;44(12):2837—44. DOI: 10.1016/j.humpath.2013.08.001. PMID: 24140425.

10. Tonon G., Modi S., Wu L. et al. t(11;19) (q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003;33(2):208—13. DOI: 10.1038/ng1083. PMID: 12539049.

11. Hori K., Sen A., Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci 2013;126(Pt 10):2135—40. DOI: 10.1242/jcs.127308. PMID: 23729744.

12. Hsieh J.J., Hayward S.D. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein—Barr virus EBNA2. Science 1995;268(5210):560—3. PMID: 7725102.

13. Dou S., Zeng X., Cortes P. et al. The recombination signal sequence-binding protein RBP-2N functions as a transcriptional repressor. Mol Cell Biol 1994;14(5): 3310—9. PMID: 8164682.

14. Ronchi C.L., Sbiera S., Altieri B. et al. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocr Relat Cancer 2015;22(4):531—43. DOI: 10.1530/ERC-15-0163. PMID: 25979380.

15. Simon D.P., Giordano T.J., Hammer G.D. Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin Cancer Res 2012;18(9):2452—64. DOI: 10.1158/1078-0432.CCR-11-2371. PMID: 22427350.

16. Toso A., Revandkar A., Di Mitri D. et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep 2014;9(1):75—89. DOI: 10.1016/j.celrep.2014.08.044. PMID: 25263564.

17. Wang X.D., Leow C.C., Zha J. et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006;290(1):66—80. DOI: 10.1016/j.ydbio.2005.11.009. PMID: 16360140.

18. Wu X., Xu K., Zhang L. et al. Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev Biol 2011;356(2):337—49. DOI: 10.1016/j.ydbio.2011.05.659. PMID: 21624358.

19. LaTulippe E., Satagopan J., Smith A. et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002;62(15):4499— 506. PMID: 12154061.

20. Santagata S., Demichelis F., Riva A. et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64(19):6854—7. DOI: 10.1158/0008-5472.CAN-04-2500. PMID: 15466172.

21. Zayzafoon M., Abdulkadir S.A., McDonald J.M. Notch signaling and ERK activation are important for the osteomi-metic properties of prostate cancer bone metastatic cell lines. J Biol Chem 2004;279(5):3662—70. DOI: 10.1074/jbc.M308158200. PMID: 14602722.

22. Peruzzi B., Athauda G., Bottaro D.P. The von Hippel—Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci USA 2006;103(39): 14531-6. DOI: 10.1073/pnas.0606850103. PMID: 16983094.

23. Turcotte S., Chan D.A., Sutphin P.D. et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008;14(1):90-102. DOI: 10.1016/j.ccr.2008.06.004. PMID: 18598947.

24. Ding M., Cui S., Li C. et al. Loss of the tumor suppressor Vhlh leads to upregula-tion of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006;12(9):1081 —7. DOI: 10.1038/nm1460. PMID: 16906157.

25. Patel U., Simpson E., Kingswood J.C., Saggar-Malik A.K. Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angio-myolipoma. Clin Radiol 2005;60(6): 665—73. DOI: 10.1016/j.crad.2005.01.009. PMID: 16038693.

26. Walker C. Molecular genetics of renal carcinogenesis. Toxicol Pathol 1998;26(1):113—20. DOI: 10.1177/019262339802600113. PMID: 9502393.

27. Aparicio L.M., Villaamil V.M., Gallego G.A. et al. Expression of Notch1 to -4 and their ligands in renal cell carcinoma: a tissue microarray study. Cancer Genomics Proteomics 2011;8(2):93—101. PMID: 21471519.

28. Gustafsson M.V., Zheng X., Pereira T. et al. Hypoxia requires Notch signaling to maintain the undifferentiated cell state. Dev Cell 2005;9(5):617—28. DOI: 10.1016/j.devcel.2005.09.010. PMID: 16256737.

29. Karbowniczek M., Zitserman D., Khabibullin D. et al. The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest 2010;120(1):93—102. DOI: 10.1172/JCI40221. PMID: 20038815.

30. Bielesz B., Sirin Y., Si H. et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010;120(11): 4040—54. DOI: 10.1172/JCI43025. PMID: 20978353.

31. Sjolund J., Johansson M., Manna S. et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 2008;118(1):217—28. DOI: 10.1172/JCI32086. PMID: 18079963.

32. Liang L., Zhang H.W., Liang J. et al. KyoT3, an isoform of murine FHL1, associates with the transcription factor RBP-J and represses the RBP-J-mediated transactivation. Biochim Biophys Acta 2008;1779(12):805—10. DOI: 10.1016/j.bbagrm.2008.08.001. PMID: 18760388.

33. Surendran K., Selassie M., Liapis H. et al. Reduced Notch signaling leads to renal cysts and papillary microadenomas. J Am Soc Nephrol 2010;21(5):819—32. DOI: 10.1681/ASN.2009090925. PMID: 20378824.

34. https://portal.gdc.cancer.gov/.

35. Greife A., Jankowiak S., Steinbring J. et al. Canonical Notch signalling is inactive in urothelial carcinoma. BMC Cancer 2014;14:628. DOI: 10.1186/1471-2407-14-628. PMID: 25167871.

36. Maraver A., Fernandez-Marcos P.J., Cash T.P. et al. NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest 2015;125(2):824—30. DOI: 10.1172/JCI78185. PMID: 25574842.

37. Rampias T., Vgenopoulou P., Avgeris M. et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med 2014;20(10):1199—205. DOI: 10.1038/nm.3678. PMID: 25194568.

38. Xu T., Wu X., Chen Q. et al. The anti-apoptotic and cardioprotective effects of salvianolic acid A on rat cardiomyocytes following ischemia/reperfusion by DUSP-mediated regulation of the ERK1/2/JNK pathway. PLoS One 2015;9(7):e102292. DOI: 10.1371/journal.pone.0102292. PMID: 25019380.

39. Kimura F., Florl A.R., Seifert H.H. et al. Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer 2001;85(12):1887—93. DOI: 10.1054/bjoc.2001.2154. PMID: 11747331.

40. Goriki A., Seiler R., Wyatt A.W. et al. Unravelling disparate roles of NOTCH in bladder cancer. Nat Rev Urol 2018;15(6):345—57. DOI: 10.1038/s41585-018-0005-1. PMID: 29643502.

41. Garcia-Cao I., Duran A., Collado M. et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005;6(6):577—83. DOI: 10.1038/sj.em-bor.7400421. PMID: 15877079.

42. Hayashi T., Gust K.M., Wyatt A.W. et al. Not all NOTCH is created equal: the oncogenic role of NOT CH2 in bladder cancer and its implications for targeted therapy. Clin Cancer Res 2016;22(12):2981—92. DOI: 10.1158/1078-0432.CCR-15-2360. PMID: 26769750.

43. Fan X., Mikolaenko I., Elhassan I. et al. Notch1 and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64(21):7787—93. DOI: 10.1158/0008-5472.CAN-04-1446. PMID: 15520184.

44. Mazur P.K., Einwachter H., Lee M. et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2010;107(30):13438—43. DOI: 10.1073/pnas.1002423107. PMID: 20624967.

45. Hanlon L., Avila J.L., Demarest R.M. et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res 2010;70(11):4280—6. DOI: 10.1158/0008-5472.CAN-09-4645. PMID: 20484026.

46. Wu Y., Cain-Hom C., Choy L. et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010;464(7291):1052—7. DOI: 10.1038/nature08878. PMID: 20393564.

47. Zhang H., Liu L., Liu C. et al. Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma. Oncotarget 2017;8(21):34362—73. DOI: 10.18632/oncotarget.16156. PMID: 28416766.

48. Luistro L., He W., Smith M. et al. Preclinical profile of a potent y-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69(19):7672—80. DOI: 10.1158/0008-5472.CAN-09-1843. PMID: 19773430.

49. Yuan X., Wu H., Xu H. et al. Notch signaling: An emerging therapeutic target for cancer treatment. Cancer Lett 2015;369(1):20—7. DOI: 10.1016/j.can-let.2015.07.048. PMID: 26341688.

50. Doody R.S., Raman R., Farlow M. et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369(4):341—50. DOI: 10.1056/NEJMoa1210951. PMID: 23883379.

51. Dobranowski P., Ban F., Contreras-Sanz A. et al. Perspectives on the discovery of NOTCH2-specific inhibitors. Chem Biol Drug Des 2018;91(3):691—706. DOI: 10.1111/cbdd.13132. PMID: 29078041.

52. Ferrarotto R., Mitani Y., Diao L. et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol 2017;35(3):352–60. DOI: 10.1200/JCO.2016.67.5264. PMID: 27870570.

53. Yen W.C., Fischer M.M., Axelrod F. et al. Targeting notch signaling with a Notch2/ Notch3 antagonist (Tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 2015;21(9):2084—95. DOI: 10.1158/1078-0432.CCR-14-2808. PMID: 25934888.

54. Lee D., Kim D., Choi Y.B. et al. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs 2016;8(5):892—904. DOI: 10.1080/19420862.2016.1171432. PMID: 27049350.

55. Andersson E.R., Lendahl U. Therapeutic modulation of Notch signaling — are we there yet? Nat Rev Drug Discov 2014;13(5):357—78. DOI: 10.1038/nrd4252. PMID: 24781550.

56. Espinoza I., Pochampally R., Xing F. et al. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther 2013;6:1249-59. DOI: 10.2147/OTT. S36162. PMID: 24043949.

57. Kangsamaksin T., Murtomaki A., Kofler N.M. et al. NOTCH decoys that selectively block DLL/NOTCH or JAG/ NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth. Cancer Discov 2015;5(2):182—97. DOI: 10.1158/2159-8290.CD-14-0650. PMID: 25387766.